Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Synageva BioPharma's Enterprise Value is €7,850.66 Mil.
Synageva BioPharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2015 was €-175.46 Mil. Therefore, Synageva BioPharma's EV-to-EBIT ratio for today is -44.74.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Synageva BioPharma's Enterprise Value is €7,850.66 Mil.
Synageva BioPharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2015 was €-170.34 Mil. Therefore, Synageva BioPharma's EV-to-EBITDA ratio for today is -46.09.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Synageva BioPharma's Enterprise Value is €7,850.66 Mil.
Synageva BioPharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2015 was €4.61 Mil. Therefore, Synageva BioPharma's EV-to-Revenue ratio for today is 1,701.86.
Synageva BioPharma Enterprise Value Historical Data
The historical data trend for Synageva BioPharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Synageva BioPharma's Enterprise Value
For the Biotechnology subindustry, Synageva BioPharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synageva BioPharma's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Synageva BioPharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Synageva BioPharma's Enterprise Value falls into.
Synageva BioPharma Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Synageva BioPharma's Enterprise Value for the fiscal year that ended in Dec. 2014 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synageva BioPharma (FRA:TMS1) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Synageva BioPharma's current Enterprise Value is €7,850.66 Mil.
Synageva BioPharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was €-175.46 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Synageva BioPharma's current Enterprise Value is €7,850.66 Mil.
Synageva BioPharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was €-170.34 Mil.
Synageva BioPharma's current Enterprise Value is €7,850.66 Mil.
Synageva BioPharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.61 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synageva BioPharma Enterprise Value Related Terms
Thank you for viewing the detailed overview of Synageva BioPharma's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Synageva BioPharma (FRA:TMS1) Business Description
Synageva BioPharma Corp is incorporated in Delaware in 1993. On November 2, 2011, Trimeris, Inc., a Delaware corporation closed a merger transaction, Reverse Merger with Synageva BioPharma Corp., Pursuant to the Merger Agreement, Private Synageva became a wholly owned subsidiary of Trimeris. As a Reverse Merger, Trimeris changed its name to Synageva BioPharma Corp. The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The Company has several proteins therapeutic in its pipeline, including enzyme replacement therapies for lysosomal storage diseases (LSDs) and protein therapeutic programs for other rare diseases that are at the stage of preclinical development. Its program, sebelipase alfa is a recombinant human lysosomal acid lipase deficiency (LAL Deficiency), currently evaluating in global Phase 3 clinical trials in infants, children and adults with LAL Deficiency. LAL Deficiency is rare autosomal recessive LSD characterized by decreased LAL enzyme activity leading to intracellular accumulation of lipids. This disease leads to medical complications with significant morbidity and early mortality. Sebelipase alfa has been granted orphan designation by the FDA, the EMA, and the Japanese Ministry of Health, Labour and Welfare. Additionally, sebelipase alfa has received Fast Track Designation by the FDA, and Breakthrough Therapy designation by the FDA for LAL Deficiency presenting in infants. The Company has not yet received approval to market this product and is not currently commercializing any other products. Sebelipase alfa is a recombinant form of the human LAL enzyme under development as an enzyme replacement therapy for LAL Deficiency. The Company is currently enrolling and dosing Phase 3 Trial of Sebelipase Alfa in Children and Adults with LAL Deficiency. It is also pursuing a development strategy for sebelipase alfa to assess safety and tolerability in a broad population of patients, including infants, children, and adults, and to demonstrate efficacy, safety and tolerability of sebelipase alfa in the treatment of LAL Deficiency. Its potential competitors include large pharmaceutical and biotechnology companies and specialty pharmaceutical companies, academic institutions, government agencies, and research institutions. The preclinical studies and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its product candidates and future products, are subject to extensive regulation by governmental authorities in the U.S. and other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:TMS1 has been successfully added to your 